[go: up one dir, main page]

WO2013134085A8 - Inhibiteurs de la bêta-sécrétase - Google Patents

Inhibiteurs de la bêta-sécrétase Download PDF

Info

Publication number
WO2013134085A8
WO2013134085A8 PCT/US2013/028796 US2013028796W WO2013134085A8 WO 2013134085 A8 WO2013134085 A8 WO 2013134085A8 US 2013028796 W US2013028796 W US 2013028796W WO 2013134085 A8 WO2013134085 A8 WO 2013134085A8
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
secretase
beta
same
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/028796
Other languages
English (en)
Other versions
WO2013134085A1 (fr
Inventor
Yuri Bukhtiyarov
Salvacion Cacatian
Lawrence Wayne Dillard
Cornelia Dorner-Ciossek
Klaus Fuchs
Lanqi Jia
Deepak S. Lala
Angel Morales-Ramos
Georg Rast
Jonathan Reeves
Suresh B. Singh
Shankar Venkatraman
Zhenrong Xu
Jing Yuan
Yi Zhao
Yajun Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Vitae Pharmaceuticals LLC
Original Assignee
Boehringer Ingelheim International GmbH
Vitae Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2013230523A priority Critical patent/AU2013230523B2/en
Priority to NZ629239A priority patent/NZ629239A/en
Priority to JP2014560985A priority patent/JP6161643B2/ja
Priority to AP2014007900A priority patent/AP4029A/en
Priority to ES13710937.7T priority patent/ES2568928T3/es
Priority to HK15106248.0A priority patent/HK1205739B/xx
Priority to EA201491534A priority patent/EA024995B1/ru
Priority to BR112014021269A priority patent/BR112014021269A2/pt
Application filed by Boehringer Ingelheim International GmbH, Vitae Pharmaceuticals LLC filed Critical Boehringer Ingelheim International GmbH
Priority to DK13710937.7T priority patent/DK2822930T3/en
Priority to IN6710DEN2014 priority patent/IN2014DN06710A/en
Priority to CN201380012529.9A priority patent/CN104271558B/zh
Priority to MX2014010625A priority patent/MX353432B/es
Priority to HRP20160415TT priority patent/HRP20160415T1/hr
Priority to MEP-2016-74A priority patent/ME02390B/fr
Priority to SG11201404600VA priority patent/SG11201404600VA/en
Priority to KR1020147026838A priority patent/KR20140138774A/ko
Priority to CA2864143A priority patent/CA2864143C/fr
Priority to EP13710937.7A priority patent/EP2822930B1/fr
Priority to SI201330173A priority patent/SI2822930T1/sl
Priority to UAA201410695A priority patent/UA113641C2/uk
Priority to RS20160246A priority patent/RS54730B1/sr
Publication of WO2013134085A1 publication Critical patent/WO2013134085A1/fr
Priority to IL233887A priority patent/IL233887A/en
Priority to TNP2014000326A priority patent/TN2014000326A1/fr
Priority to ZA2014/05846A priority patent/ZA201405846B/en
Priority to PH12014501963A priority patent/PH12014501963B1/en
Publication of WO2013134085A8 publication Critical patent/WO2013134085A8/fr
Anticipated expiration legal-status Critical
Priority to MA37375A priority patent/MA35945B1/fr
Priority to AU2017236042A priority patent/AU2017236042B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/02—Thiocyanates
    • C07C331/14—Thiocyanates having sulfur atoms of thiocyanate groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention a trait à des acylguanidines spirocycliques et leur utilisation en tant qu'inhibiteurs de l'activité de l'enzyme bêta-sécrétase (BACEI), des compositions pharmaceutiques les contenant, et des procédés pour les utiliser en tant qu'agents thérapeutiques dans le traitement de troubles neurodégénératifs, des troubles caractérisés par un déclin cognitif, une déficience cognitive, la démence et des maladies caractérisées par la production d'agrégats de bêta-amyloïde.
PCT/US2013/028796 2012-03-05 2013-03-04 Inhibiteurs de la bêta-sécrétase Ceased WO2013134085A1 (fr)

Priority Applications (27)

Application Number Priority Date Filing Date Title
MEP-2016-74A ME02390B (fr) 2012-03-05 2013-03-04 Inhibiteurs de la bêta-sécrétase
JP2014560985A JP6161643B2 (ja) 2012-03-05 2013-03-04 β−セクレターゼ阻害剤
AP2014007900A AP4029A (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase
ES13710937.7T ES2568928T3 (es) 2012-03-05 2013-03-04 Inhibidores de la beta-secretasa
HK15106248.0A HK1205739B (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase
EA201491534A EA024995B1 (ru) 2012-03-05 2013-03-04 Спироциклические ацилгуанидины в качестве ингибиторов бета-секретазы (bace1)
BR112014021269A BR112014021269A2 (pt) 2012-03-05 2013-03-04 "inibidores da beta-secretase, seus usos, e composição farmacêutica"
KR1020147026838A KR20140138774A (ko) 2012-03-05 2013-03-04 베타-세크레타아제의 억제제들
DK13710937.7T DK2822930T3 (en) 2012-03-05 2013-03-04 BETA-SECRETASE INHIBITORS
IN6710DEN2014 IN2014DN06710A (fr) 2012-03-05 2013-03-04
CN201380012529.9A CN104271558B (zh) 2012-03-05 2013-03-04 β-分泌酶抑制剂
MX2014010625A MX353432B (es) 2012-03-05 2013-03-04 Inhibidores de la beta-secretasa.
HRP20160415TT HRP20160415T1 (hr) 2012-03-05 2013-03-04 Inhibitori beta-sekretaze
SG11201404600VA SG11201404600VA (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase
CA2864143A CA2864143C (fr) 2012-03-05 2013-03-04 Inhibiteurs de la beta-secretase
AU2013230523A AU2013230523B2 (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase
NZ629239A NZ629239A (en) 2012-03-05 2013-03-04 Inhibitors of beta-secretase
EP13710937.7A EP2822930B1 (fr) 2012-03-05 2013-03-04 Inhibiteurs de la bêta-sécrétase
SI201330173A SI2822930T1 (sl) 2012-03-05 2013-03-04 Inhibitorji beta-sekretaze
UAA201410695A UA113641C2 (xx) 2012-03-05 2013-03-04 Інгібітори бета-секретази
RS20160246A RS54730B1 (sr) 2012-03-05 2013-03-04 Inhibitori beta sekretaze
IL233887A IL233887A (en) 2012-03-05 2014-07-30 Beta-Scarase inhibitors
TNP2014000326A TN2014000326A1 (en) 2012-03-05 2014-07-31 Inhibitors of beta-secretase
ZA2014/05846A ZA201405846B (en) 2012-03-05 2014-08-08 Inhibitors of beta-secretase
PH12014501963A PH12014501963B1 (en) 2012-03-05 2014-09-02 Inhibitors of beta-secretase
MA37375A MA35945B1 (fr) 2012-03-05 2014-09-26 Inhibiteurs de la bêta-sécrétase
AU2017236042A AU2017236042B2 (en) 2012-03-05 2017-10-02 Inhibitors of beta-secretase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606786P 2012-03-05 2012-03-05
US61/606,786 2012-03-05

Publications (2)

Publication Number Publication Date
WO2013134085A1 WO2013134085A1 (fr) 2013-09-12
WO2013134085A8 true WO2013134085A8 (fr) 2014-09-04

Family

ID=47902355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/028796 Ceased WO2013134085A1 (fr) 2012-03-05 2013-03-04 Inhibiteurs de la bêta-sécrétase

Country Status (39)

Country Link
US (4) US8981112B2 (fr)
EP (1) EP2822930B1 (fr)
JP (1) JP6161643B2 (fr)
KR (1) KR20140138774A (fr)
CN (1) CN104271558B (fr)
AP (1) AP4029A (fr)
AR (1) AR090241A1 (fr)
AU (2) AU2013230523B2 (fr)
BR (1) BR112014021269A2 (fr)
CA (1) CA2864143C (fr)
CL (1) CL2014002334A1 (fr)
CO (1) CO7091177A2 (fr)
CY (1) CY1117543T1 (fr)
DK (1) DK2822930T3 (fr)
EA (1) EA024995B1 (fr)
EC (1) ECSP14020640A (fr)
ES (1) ES2568928T3 (fr)
HR (1) HRP20160415T1 (fr)
HU (1) HUE027289T2 (fr)
IL (1) IL233887A (fr)
IN (1) IN2014DN06710A (fr)
MA (1) MA35945B1 (fr)
ME (1) ME02390B (fr)
MX (1) MX353432B (fr)
MY (1) MY171091A (fr)
NZ (1) NZ629239A (fr)
PE (1) PE20141972A1 (fr)
PH (1) PH12014501963B1 (fr)
PL (1) PL2822930T3 (fr)
RS (1) RS54730B1 (fr)
SG (1) SG11201404600VA (fr)
SI (1) SI2822930T1 (fr)
SM (1) SMT201600114B (fr)
TN (1) TN2014000326A1 (fr)
TW (1) TWI557112B (fr)
UA (1) UA113641C2 (fr)
UY (1) UY34654A (fr)
WO (1) WO2013134085A1 (fr)
ZA (1) ZA201405846B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294178B1 (fr) 2008-05-23 2014-07-16 Siwa Corporation Procédés facilitant la régénération
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
EP2847177B1 (fr) 2012-05-09 2017-10-11 Boehringer Ingelheim International GmbH Methodes pour la preparation d'oxetan-3-ylmethanamines
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
US9290477B2 (en) 2012-09-28 2016-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of β-secretase
US9079832B2 (en) 2012-11-21 2015-07-14 Boehringer Ingelheim International Gmbh Process for making N-sulfinyl α-amino amides
JP6976847B2 (ja) 2014-09-19 2021-12-08 シワ コーポレイション 炎症及び自己免疫障害を治療するための抗ａｇｅ抗体
UY36347A (es) * 2014-10-07 2016-04-01 Astrazeneca Ab Compuestos y su uso como inhibidores de bace
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
KR102536017B1 (ko) 2016-02-19 2023-05-24 시와 코퍼레이션 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물
AU2017250301A1 (en) 2016-04-15 2018-11-15 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
CA3039026A1 (fr) * 2016-09-07 2018-03-15 The Regents Of The University Of California Antagonistes allosteriques du recepteur 1 du facteur de liberation de la corticotropine (crfr1) qui diminuent la p-tau et ameliorent la cognition
CA3059803A1 (fr) 2017-04-13 2018-10-18 Siwa Corporation Anticorps monoclonal humanise de produit final de glycation avancee
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020198583A1 (fr) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Inhibiteurs de jak bicycliques et leurs utilisations
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
BE1027699B1 (fr) * 2021-01-28 2022-04-01 Trasis S A Procédé de purification de macro-agrégats de sérumalbumine humaine radiomarqués
CN113082209A (zh) * 2021-03-31 2021-07-09 中国科学技术大学 Cd4+t细胞源性bace1、ep2、ep4作为阿尔茨海默病治疗靶点的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5745185A (en) 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
CA2113818A1 (fr) 1991-08-28 1993-03-18 Robert C. Gadwood Benzopyranimidazolines spirocycliques
EP0758313A4 (fr) 1994-05-06 1999-09-15 Pharmacopeia Inc Bibliotheque combinatoire de dihydrobenzopyranes
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2548388A1 (fr) 2003-12-15 2005-06-30 Schering Corporation Inhibiteurs de protease aspartyle heterocyclique
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200602048A (en) 2004-06-16 2006-01-16 Wyeth Corp Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
EP1756087B1 (fr) 2004-06-16 2009-10-07 Wyeth Dérivés d'amino-5,5-diphénylimidazolone servant à inhiber la bêta-secrétase
EP1804794B1 (fr) 2004-10-13 2013-07-31 Merck Sharp & Dohme Corp. Composés de spiropiperidine utilisés comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
AU2006259675A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
AU2006259609A1 (en) 2005-06-14 2006-12-28 Pharmacopeia, Inc. Aspartyl protease inhibitors
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
CN101233274B (zh) 2005-07-29 2011-03-16 皇家飞利浦电子股份有限公司 从蒸汽熨斗产生蒸汽喷发的方法
CN101273018A (zh) 2005-09-26 2008-09-24 惠氏公司 用于β分泌酶（BACE）抑制剂的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑酮化合物
US8173642B2 (en) 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
DE102005057688A1 (de) 2005-12-01 2007-06-14 Endress + Hauser Flowtec Ag Vorrichtung zur Bestimmung und/oder Überwachung des Massedurchflusses eines gasförmigen Mediums
WO2007078813A2 (fr) 2005-12-19 2007-07-12 Wyeth DÉRIVÉS DE 2-AMINO-5-PIPÉRIDINYLIMIDAZOLONE ET APPLICATIONS À LA MODULATION DE LA ß-SECRÉTASE
WO2007076284A2 (fr) 2005-12-20 2007-07-05 Fieldbus Foundation Systeme et procede pour mettre en oeuvre des systemes instrumentes de securite
WO2007100536A1 (fr) 2006-02-24 2007-09-07 Wyeth COMPOSES DE DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] POUR L'INHIBITION DE LA β-SECRETASE
AU2007258435A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
ZA200900103B (en) 2006-07-18 2010-03-31 Astellas Pharma Inc Aminoindane derivative or salt thereof
JP2010502705A (ja) 2006-09-07 2010-01-28 メルク エンド カムパニー インコーポレーテッド アルツハイマー病の治療用としてのスピロピペリジンベータセクレターゼ阻害剤
WO2008076044A1 (fr) 2006-12-20 2008-06-26 Astrazeneca Ab Nouveaux 2-amino-5, 5-diaryl-imidazol-4-ones
TW200831484A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
TW200831091A (en) 2006-12-20 2008-08-01 Astrazeneca Ab New compounds
PE20090160A1 (es) 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
AR065814A1 (es) 2007-03-23 2009-07-01 Wyeth Corp Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados.
TW200902526A (en) 2007-04-24 2009-01-16 Shionogi & Amp Co Ltd Aminodihydrothiazin derivative substituted with a cyclic group
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
UY31083A1 (es) 2007-05-15 2009-01-05 Astrazeneca Ab Derivados de sulfoximinas para la inhibicion de b-secretasa
EP2077637B1 (fr) 2007-12-12 2020-03-11 Alcatel Lucent Système et procédé de protection d'informations de données utiles dans une transmission radio
JP5258904B2 (ja) 2008-02-18 2013-08-07 エフ．ホフマン−ラ ロシュ アーゲー ４，５−ジヒドロオキサゾール−２−イルアミン誘導体
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
US8501733B2 (en) 2008-07-28 2013-08-06 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (fr) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dérivé de spiroaminodihydrothiazine
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CA2736130C (fr) 2008-09-11 2014-01-14 Amgen Inc. Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
NZ592823A (en) 2008-11-23 2012-12-21 Pfizer Spirocyclic lactams for treating neurodegenerative and/or neurological disorders
MX2011009571A (es) * 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
WO2011072064A1 (fr) 2009-12-08 2011-06-16 Array Biopharma Inc. Spiro[chromane-4,4'-imidazol]ones en tant qu'inhibiteurs de bêta-sécrétase
US8889703B2 (en) 2010-02-24 2014-11-18 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
US20120065195A1 (en) 2010-03-31 2012-03-15 Clark Christopher T Compounds for treating neurodegenerative diseases
US8415483B2 (en) * 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑

Also Published As

Publication number Publication date
MX2014010625A (es) 2015-04-08
BR112014021269A2 (pt) 2017-07-04
IL233887A0 (en) 2014-09-30
ECSP14020640A (es) 2015-06-30
CO7091177A2 (es) 2014-10-21
IN2014DN06710A (fr) 2015-05-22
AU2013230523A1 (en) 2014-09-18
TN2014000326A1 (en) 2015-12-21
TWI557112B (zh) 2016-11-11
AU2017236042B2 (en) 2019-01-03
UY34654A (es) 2013-09-30
HRP20160415T1 (hr) 2016-06-03
JP2015511958A (ja) 2015-04-23
AU2017236042A1 (en) 2017-10-26
US8981112B2 (en) 2015-03-17
DK2822930T3 (en) 2016-04-25
JP6161643B2 (ja) 2017-07-12
PH12014501963A1 (en) 2014-11-17
ME02390B (fr) 2016-09-20
EA201491534A1 (ru) 2014-12-30
PL2822930T3 (pl) 2016-09-30
US9526727B2 (en) 2016-12-27
AP2014007900A0 (en) 2014-08-31
SI2822930T1 (sl) 2016-09-30
CY1117543T1 (el) 2017-04-26
SMT201600114B (it) 2016-08-31
EA024995B1 (ru) 2016-11-30
US9949975B2 (en) 2018-04-24
KR20140138774A (ko) 2014-12-04
CL2014002334A1 (es) 2015-04-17
AP4029A (en) 2017-02-05
NZ629239A (en) 2016-04-29
WO2013134085A1 (fr) 2013-09-12
IL233887A (en) 2017-09-28
SG11201404600VA (en) 2014-10-30
ZA201405846B (en) 2017-08-30
RS54730B1 (sr) 2016-10-31
AU2013230523B2 (en) 2017-10-05
US20180344734A1 (en) 2018-12-06
CN104271558B (zh) 2016-08-24
UA113641C2 (xx) 2017-02-27
US20130289050A1 (en) 2013-10-31
TW201339139A (zh) 2013-10-01
HK1205739A1 (zh) 2015-12-24
PE20141972A1 (es) 2014-12-28
HUE027289T2 (en) 2016-09-28
ES2568928T3 (es) 2016-05-05
CA2864143C (fr) 2020-04-14
PH12014501963B1 (en) 2014-11-17
AR090241A1 (es) 2014-10-29
US20170196867A1 (en) 2017-07-13
MY171091A (en) 2019-09-25
CN104271558A (zh) 2015-01-07
EP2822930B1 (fr) 2016-01-20
CA2864143A1 (fr) 2013-09-12
MA35945B1 (fr) 2014-12-01
MX353432B (es) 2018-01-11
US20150150872A1 (en) 2015-06-04
EP2822930A1 (fr) 2015-01-14

Similar Documents

Publication Publication Date Title
WO2013134085A8 (fr) Inhibiteurs de la bêta-sécrétase
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
TN2015000032A1 (en) Inhibitors of beta-secretase
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
PH12015500106A1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EA201491116A1 (ru) Производные 6-дифторметил-5,6-дигидро-2h-[1,4]оксазин-3-амина
MX370113B (es) Moduladores alostericos positivos del receptor muscarinico m2.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MY196473A (en) 7-Substituted 1-Aryl-Naphthyridine-3-Carboxylic Acid Amides and use Thereof
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
WO2014052398A8 (fr) Inhibiteur de beta-secrétase
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos
MA37955A1 (fr) Inhibiteurs de bêta-secrétase
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
WO2013114403A8 (fr) 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates substitués destinés au traitement du diabète et de troubles apparentés
MA37780A1 (fr) Nouveaux acides 5-aminotétrahydrochinolino-2-carboxyliques et leur utilisation
WO2014082738A8 (fr) Hétéroquinoline-3-carboxamides utilisés en tant que modulateurs kcnq2/3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13710937

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 233887

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2864143

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2014002334

Country of ref document: CL

Ref document number: 001347-2014

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/010625

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2014560985

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201491534

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2013710937

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013230523

Country of ref document: AU

Date of ref document: 20130304

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147026838

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2014000559

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 14215177

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: A201410695

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 13587

Country of ref document: GE

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: IDP00201405981

Country of ref document: ID

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014021269

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2016/0246

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112014021269

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140828